Defining long COVID using a population-based SARS-CoV-2 survey in California

Vaccine. 2024 Dec 2;42(26):126358. doi: 10.1016/j.vaccine.2024.126358. Epub 2024 Sep 17.

Abstract

Background: More than four years after the start of the COVID-19 pandemic, understanding of SARS-CoV-2 burden and post-acute sequela of COVID (PASC), or long COVID, continues to evolve. However, prevalence estimates are disparate and uncertain. Leveraging survey responses from a large serosurveillance study, we assess prevalence estimates using five different long COVID definitions among California residents.

Methods: The California Department of Public Health (CDPH) conducted a cross-sectional survey that included questions about acute COVID-19 infection and recovery. A random selection of California households was invited to participate in a survey that included demographic information, clinical symptoms, and COVID-19 vaccination history. We assessed prevalence and predictors of long COVID among those previously testing positive for SARS-CoV-2 across different definitions using logistic regression.

Findings: A total of 2883 participants were included in this analysis; the majority identified as female (62.5 %), and the median age was 39 years (interquartile range: 17-55 years). We found a significant difference in long COVID prevalence across definitions with the highest prevalence observed when participants were asked about incomplete recovery (20.9 %, 95 % confidence interval [CI]: 19.4-22.5) and the lowest prevalence was associated with severe long COVID affecting an estimated 4.9 % (95 % CI 4.1-5.7) of the participant population. Individuals that completed the primary vaccination series had significantly lower prevalence of long COVID compared to those that did not receive COVID vaccination.

Interpretation: There were significant differences in the estimated prevalence of long COVID across different definitions. People who experience a severe initial COVID-19 infection should be considered at a higher probability for developing long COVID.

Funding: Centers for Disease Control and Prevention - Epidemiology and Laboratory Capacity.

Keywords: California; Long COVID; Long COVID-19; PASC; Post-acute sequelae of SARS-CoV-2 infection; Public health; SARS-CoV-2.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • COVID-19 Vaccines / administration & dosage
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • California / epidemiology
  • Cross-Sectional Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Post-Acute COVID-19 Syndrome
  • Prevalence
  • SARS-CoV-2* / immunology
  • Surveys and Questionnaires
  • Young Adult

Substances

  • COVID-19 Vaccines